
NewLimit: A biotech firm innovating epigenetic therapies to extend health span and treat age-related diseases.
Founded with a mission to extend the human health span, NewLimit is a biotechnology company focused on developing epigenetic reprogramming therapies. The company aims to treat age-related diseases by reprogramming cells to younger states, addressing significant unmet medical needs. NewLimit's innovative approach targets both specific diseases and broader longevity, positioning itself at the forefront of the biotech industry.
NewLimit has attracted notable talent and investors, contributing to its rapid advancements in epigenetic therapy. The company's achievements include pioneering research that has the potential to revolutionize treatments for age-related conditions. By focusing on cellular reprogramming, NewLimit is making a substantial impact on the future of healthcare and longevity, aiming to improve quality of life as people age.

Retro Biosciences
retro.bio

Altos Labs
altoslabs.com

Rejuveron Life Sciences
rejuveron.com

Rejuvitas
rejuvitas.com

Epic-Bio
epic-bio.com

Longeveron
longeveron.com

AgeX Therapeutics

Rejuvenation Technologies Inc.

Lifespan Vision Ventures

New Frontier Bio
newfrontierbio.com

Regenerative Bio
regen-bio.us

iReprogram
ireprogram.com

Endpoint Health

Juvenescence
juvlabs.com

ProFound Therapeutics
profoundtx.com
Companies similar to NewLimit include Retro Biosciences, Altos Labs, Rejuveron Life Sciences and Rejuvitas.
NewLimit was founded in 2022.
NewLimit's headquarters is located in South San Francisco, CA, US.
NewLimit's most recent funding round was for $40M (USD) in May 2023.
As of May 16, 2023, NewLimit has raised a total of $40M (USD).
NewLimit has 7 employees as of Feb 5, 2024.